ECRONICON OPEN ACCESS

EC MICROBIOLOGY
Review Article

Vitiligo: Causes, Treatment and Hazards

Aishah Nabil Azam[1]*, Sarah Mohammad Alshawi[2], Shaza Omar H Alorabi[2], Rolan Mohammad Khan[3], Abdullah Hatem Aman[4], Wafa Ibrahim Alsaab[5], Zainab Jaffer Al Shaikh[6], Fatimah Hassan A Al Turaifi[7], Ahmad Naif Alharbi[1], Manal Abdullah Alshammari[8], Sarah Fahad Alrayyes[9], Alaa Daif Allah Althobaiti[10] and Nojoud Ali Al-Fareh[11]

[1]Taibah University, Medina, Saudi Arabia
[2]King Abdulaziz University, Jeddah, Saudi Arabia
[3]Ibn Sina College, Jeddah, Saudi Arabia
[4]King Saud Medical City, Riyadh, Saudi Arabia
[5]Princess Nourah University, Riyadh, Saudi Arabia
[6]Buqayq General Hospital, Saudi Arabia
[7]Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
[8]University of Hail, Saudi Arabia
[9]Prince Mutaib Bin Abdulaziz Hospital, Saudi Arabia
[10]Taif University, Taif, Saudi Arabia
[11]King Khalid University, Abha, Saudi Arabia

***Corresponding Author**: Aishah Nabil Azam, Taibah University, Medina, Saudi Arabia.

Received: August 26, 2017*;* **Published:** August 28, 2017

Abstract

Vitiligo is one of the most common dermatological disorders, showing up as at least one white macule or patches and affecting up to two percent of the population around the world. The undesirable aesthetic properties of vitiligo, particularly facial, may bring about critical negative psychosocial effects, especially a rate of depression twice that of the overall public. The exact cause of vitiligo is unknown; be that as it may, current hypotheses concentrate on the destruction of melanocytes by autoimmune mechanisms, neural mechanisms, oxidant-antioxidant mechanisms, or intrinsic defects of melanocytes. There are several treatment choices, for example, medications, phototherapy, laser therapy, and surgical therapy.

Keywords: *Vitiligo; Melanocytes; Surgical Therapy; Laser Therapy; Phototherapy*

Introduction

Vitiligo is a pigmentary disorder of the skin, which is described by circumscribed depigmented macules and patches. Vitiligo is a dynamic disorder in which a few or the greater part of the melanocytes in the affected skin are specifically destroyed. Vitiligo influences 0.5 - 2% of the total populace, and the average age of beginning is 20 years. Whereas vitiligo might be clearer in individuals with darker skin, this disorder does not have a racial or ethnic inclination [1]. The condition is as often as possible related with autoimmune origin, with thyroid abnormalities being the most common.

The undesirable aesthetic properties of vitiligo, mainly facial, might result in substantial negative psychosocial effects, remarkably a rate of depression twice that of the overall population [2]. In a few societies, vitiligo is not surely understood. The depigmentation of vitiligo is thought to come about because of sexually transmitted contaminations, or of leprosy, and may have a damaging effect on educational, social, and employment chances. Patients might feel uncomfortable or embarrassed of such a noticeable disorder. Studies have demonstrated that vitiligo is connected with a greater burden of disease to patients, particularly those in populations with dark skin. Thus, treatment, in spite of the fact that not medicinally important, gives substantial psychosocial additions to the patient, expanding their quality of life [1,3,4].

Late examinations have started to uncover the pathophysiology of vitiligo. A trigger occasion is thought to actuate stress reactions in the skin that elicit an immune system reaction in genetically susceptible people that at last focuses on the melanocytes known to have an inherited fragility, predisposing people to improve vitiligo [5]. The most critical progress in our comprehension of illness etiology has been made on three fronts: characterizing the stress responses activated by vitiligo triggers, delineating the autoimmune components that cause disease progression, and recognizing susceptibility genes. There are currently no treatments for vitiligo that efficiently encourage complete repigmentation with long-lasting effects while avoiding reappearance. Total depigmentation therapy using monobenzone (for severe cases) is presently the only treatment accepted by the US Food and Drug Administration (FDA) for vitiligo; novel methods to avoid further loss and promote repigmentation are being considered and can yield effective, long-lasting therapies. These endeavors are bolstered by worldwide coordinated efforts that have drawn up consensus guidelines for disease classification [6], categorizing severity [7], and result measures that are additionally valuable for clinical investigations [8].

Vitiligo is characterized by incomplete penetrance, multiple susceptibility loci, and genetic heterogeneity [9]. Family and twin examinations have demonstrated that inheritance is complex and likely includes both genetic and environmental features. Moreover, it is assumed that genetic features can affect the time of beginning of vitiligo [10]. The inheritance of vitiligo might incorporate genes related with the biosynthesis of melanin, a reaction to oxidative stress, and regulation of autoimmunity [11]. Current research has not distinguished any relationship with a specific HLA sort in a reliable way. There is reason to trust that segmental vitiligo and non-segmental vitiligo may have distinct genetic mechanisms, which could represent for their distinctive responses to treatment.

Symptoms and signs

Vitiligo is quite often identified clinically upon physical examination. Vitiligo shows as obtained depigmented macules or patches encompassed by typical skin. The macules are chalk or drain white in shading and are are well defined. Lesions can be linear, oval, or round in form. The margins might be curved [1]. Lesions expand outwardly after some time at a flighty rate. Lesions go from millimeters to centimeters in measure. A Wood lamp might be important to see lesions on patients with lighter skin. The most well-known destinations of vitiligo inclusion are the face, neck, lower arms, feet, dorsal hand, fingers, and scalp. At the point when found on the face, lesions might support a periocular or perioral spreading. In the setting of widespread or generalized vitiligo, lesions may likewise occur around the genital locale, areola, and nipple. Moreover, lesions may happen in areas habitually subjected to trauma, for example, bony prominences, elbows, and knees. Koebner phenomenons are defined as the advancement of vitiligo in destinations of trauma, for example, a cut, burn, or abrasion. Koebnerization may happen in upwards of 20 - 60% of vitiligo patients [12].

Body hair in vitiliginous macules might be depigmented. This is known as leukotrichia, and it might show a poor prognosis with respect to repigmentation treatment [13]. Spontaneous repigmentation of depigmented hair is doubtfully to happen.

The exact cause of vitiligo is still unknown; nevertheless, current theories concentrate on the destruction of melanocytes by autoimmune mechanisms, neural mechanisms, oxidant-antioxidant mechanisms, or intrinsic defects of melanocytes. See Pathophysiology for more detail.

Trichrome vitiligo is a clinical variation described by a moderate zone of hypopigmentation situated between the depigmented center and the peripheral unaffected skin. The characteristic advancement of the hypopigmented ranges is movement to full depigmentation. This results in three shades of color in a similar patient, as in the picture underneath. The introduction and shades of trichrome vitiligo fluctuates relying upon the regular skin shade of the patient.

Marginal inflammatory vitiligo is an extremely uncommon variation in which a red, raised border is available at beginning or may seem a while or years after introductory beginning. Mild pruritus might be available (Figure 1). Quadrichrome vitiligo is another variant of vitiligo, which reflects the presence of a fourth color (dark brown) at sites of perifollicular repigmentation.



Figure 1: *Marginal inflammatory vitiligo.*

Vitiligo might be separated into two groups: segmental and non-segmental. It is critical to take note of that other grouping frameworks exist that separate sorts of vitiligo in view of having a limited or summed up dispersion, with confined inferring the sore is confined to a particular territory and summed up suggesting more than one region is included. In any case, the refinement amongst segmental and non-segmental might be the most valuable to the clinician, as it affects movement, visualization, and treatment.

Segmental vitiligo

This sort shows as at least one macules that may take after the lines of Blaschko. It is one-sided and does not cross the midline. Segmental vitiligo generally has an early beginning and quickly spreads in the influenced area. The course of segmental vitiligo can capture, and depigmented patches can hold on unaltered for the life of the patient. This sort of vitiligo is not related with thyroid or other immune system issue (Figure 2).



Figure 2: *Segmental vitiligo.*

Non-segmental vitiligo

Non-segmental vitiligo has filled in as an umbrella term to incorporate a wide range of vitiligo that can't be named segmental vitiligo [14]. Of note, non-segmental vitiligo is more unequivocally connected than segmental vitiligo to markers of autoimmunity or inflammation, for example, halo nevi and thyroid antibodies [15].

Examples of non-segmental vitiligo include the following (Figure 3):



Figure 3: *Non-segmental vitiligo.*

- **Focal vitiligo**: This is characterized by one or more macules in a limited area that do not follow a segmental distribution.
- **Generalized vitiligo**: This follows a non-segmental distribution and is more widespread than localized or focal vitiligo.

Subtypes of generalized vitiligo include the following:

- **Acrofacial vitiligo:** Depigmentation occurs on the distal fingers and periorificial areas.
- **Vulgaris vitiligo:** This is characterized by scattered patches that are widely distributed.
- **Universal vitiligo:** Complete or nearly complete depigmentation of the body occurs.

Approaches of Treatment

Several sorts of medicines, phototherapy, laser treatment, and surgical treatment exist. Nonetheless, it is essential to take note of that in patients with lighter skin, no mediation might be required. Rather, steady sun protection might be the best approach with a specific end goal to maintain a strategic distance from the encompassing ordinary skin from ending up more tan and making the lesions more clear. At the point when treatment is essential, topical steroids, topical calcineurin inhibitors, and narrow-band ultraviolet (UV)– B phototherapy are broadly utilized and are presently viewed as the backbones of treatment. In any case, treatment must be individualized and patients ought to be made mindful of the dangers related with treatment. No single therapy for vitiligo delivers typically great outcomes in all patients, and the response to treatment is inconstant.

A few sorts of vitiligo or lesions in specific areas might be pretty much receptive to treatment. Segmental vitiligo and a period of beginning more youthful than fourteen years have been related with more refractory disease [16]. Amid treatment, pigment cells emerge and proliferate from the pilosebaceous unit, spare epidermal melanocytes [17], and the border of lesions, and move up to 2 - 4 mm from the edge.

Laser therapy

The excimer laser produces monochromatic rays at 308 nm to treat constrained, stable patches of vitiligo. This new treatment is an effective, safe, and well-tolerated treatment for vitiligo. Be that as it may, treatment is costly. Localized lesions of vitiligo are treated twice week by week for a normal of 24 - 48 sessions. Excimer laser has been combined with both topical tacrolimus and short-term systemic corticosteroids in the setting of segmental vitiligo, which is a sort known to be more impervious to repigmentation in some patients.

Studies suggest that segmental vitiligo has a better repigmentation response with excimer laser treatment used at earlier stages of the disease [18]. Moreover, the utilization of khellin 4% ointment in combination with monochromatic excimer light (MEL) at 308 nm has been examined and might be a valid therapeutic option deserving of attention in the treatment of vitiligo [19].

Phototherapy

Phototherapy actuates agreeable repigmentation in a larger part of patients with early or localized ailment [20]. Prolonged phototherapy courses ought to be supported, as a treatment time of no less than a half year might be important to precisely evaluate the responsiveness to the phototherapy [21]. It ought to be noticed that phototherapy causes the ordinary skin encompassing the injuries to tan, in this manner making the lesion more observable. This might be cosmetically unsuitable in a few patients; subsequently, cautious directing encompassing patient desires and results is essential before starting treatment.

Narrowband UV-B (NB-UVB) is broadly utilized and has turned into the primary decision of phototherapy for grown-ups and youngsters with summed up vitiligo. Wavelengths of 311 - 312 nm ordinarily are utilized. Treatment recurrence is 2 - 3 times week by week. This treatment can be securely utilized as a part of youngsters, pregnant ladies, and lactating ladies. Nonetheless, phototherapy might be troublesome in pediatric patients who might be not able to collaborate. Here and now antagonistic impacts of NB-UVB incorporate consuming, pruritus, and xerosis. Psoralen photochemotherapy includes the utilization of psoralens joined with UV-A radiation and is otherwise called PUVA. Psoralens can be connected either topically or taken orally, trailed by an introduction to simulated UV-A radiation or regular daylight. Unfavorable impacts incorporate phototoxic impacts, sickness, and danger of skin malignancy. PUVA has generally been supplanted by NB-UVB, which is exceedingly viable and has less unfavorable impacts. Writing audits from 2017 have demonstrated that NB-UVB treatment has a general betterreaction over treatment with PUVA [21]. Additional preferences of NB-UVB over PUVA include shorter treatment times, no medication costs, no nausea, and no requirement for consequent photoprotection.

Topical therapies

Afamelanotide

Afamelanotide is a rising treatment for vitiligo that is an enduring synthetic analog of alpha-melanocyte– fortifying hormone (α-MSH) [22,23]. Afamelanotide ties to the melanocortin-1 receptor and fortifies melanocyte multiplication and melanogenesis. The introduce of the treatment the information that patients with vitiligo display deserts in the melanocortin framework, which show as diminished levels of α-MSH in both fundamental flow and skin injuries [24]. Afamelanotide is conveyed as a subcutaneous implant. A 55-understanding stage I/II consider demonstrated that when utilized as a part of conjunction with NB-UVB, a 7-to 10-day discharge embed of 16 mg afamelanotide created quicker repigmentation of facial and furthest point injuries than NB-UVB alone. Unfavorable responses included hyperpigmentation of typical skin, sickness, and stomach torment [23,25].

Topical JAK inhibitor therapy

Topical Janus kinase (JAK) inhibitor therapy likewise might be a rising alternative [26]. A little confirmation of-idea examines utilizing twice-day by day topical ruxolitinib 1.5% indicated promising outcomes [27]. Outcomes measured utilizing the Vitiligo Area Scoring Index (VASI) demonstrated 23% general change at week 20. Additionally inquire about is required, yet topical JAK inhibitor treatment may offer guarantee in vitiligo treatment.

Systemic corticosteroid therapy

Systemic steroids (prednisone) have been used, even though this treatment technique is not recommended owing to its toxicity.

Depigmentation therapy

If vitiligo is prevalent and attempts at repigmentation do not produce satisfactory outcomes, depigmentation can be attempted in very cautiously selected patients. The long-term social and emotional significances of depigmentation should be considered. Depigmentation

must not be attempted unless the patient fully understands that the treatment outcomes in permanent depigmentation. Some authorities have recommended consultation with a mental health professional to discuss potential social consequences of depigmentation [28]. A twenty percent cream of monobenzylether of hydroquinone is used twice every day for 3 a year. Burning or itching may happen. Hypersensitive contact dermatitis might be seen [29]. The poisonous quality of monobenzylether of hydroquinone has been regarded mellow; notwithstanding, no exploration has been performed on the wellbeing of utilizing the medication over huge surface ranges of skin to prompt boundless pigmentation [30]. Accordingly, it is proposed that depigmentation treatment be restricted to the sores that are most troublesome to the patient, for example, ones on the face and hands.

Vitamin D analogs

Vitamin D analogs, especially calcipotriol and tacalcitol, have been utilized as topical helpful specialists in vitiligo. They focus on the neighborhood resistant reaction and follow up on particular T-cell initiation. They do this by restraint of the change of T cells (right on time to late G1 stage) and hindrance of the statement of different proinflammatory cytokines that encode tumor rot factor-alpha and interferon-gamma. This vitamin D3 mixes impact melanocyte development and separation, notwithstanding up-directing melanogenesis through pathways that are initiated by particular ligand receptors (e.g. endothelin receptor and c-pack) [31]. More research is expected to look at the adequacy of calcipotriol as a treatment for vitiligo, as it stays disputable. Some examinations have discovered that the expansion of calcipotriol to mix medications including NB-UVB, PUVA, or topical steroids enhanced repigmentation, while others have discovered no critical contrasts [32-34]. While the part of calcipotriol in vitiligo treatment is as yet not totally clear, it is more probable that it could go about as a supplemental treatment instead of a monotherapy.

Calcineurin inhibitors

Topical tacrolimus ointment (0.03% or 0.1%) and pimecrolimus cream are compelling treatments for vitiligo, especially when the illness includes the head and neck. These might be utilized as a part of blend with topical steroids. Studies have proposed that expanding topical calcineurin inhibitors with laser treatment or NB-UVB may yield better treatment outcomes [35].

Steroids

A topical corticosteroid planning is frequently picked as a first-line treatment for restricted vitiligo since it is simple and helpful for patients. The outcomes of treatment have been accounted for as tolerably successful, especially in patients with localized vitiligo and additionally an inflammatory segment to their vitiligo. Contingent upon the territory being dealt with, a respectably strong topical steroid can be connected day by day for a time of months and after that decreased relying upon reaction. Patients ought to be checked nearly for the likelihood of steroid atrophy.

Surgical Treatment

Surgical treatment for vitiligo consist of autologous punch and suction blister grafts, split thickness grafts, needling, and non-cultured epidermal cell suspension also known as melanocyte keratinocyte transplantation (MKTP) [36]. The latter technique involves the application of an autologous cell mixture to an abraded recipient site. This is often followed by continued treatment with phototherapy. Improvements to this technique have made it an effective and well-tolerated procedure with high repigmentation rates [37,38].

Conclusion

Current medical and surgical therapies for vitiligo, mainly when used in combination, have shown some success in the stabilization and repigmentation of vitiligo. New therapies are possible, and the future for vitiligo is encouraging. Moreover, international collaborations to establish common outcome criteria will support these efforts. Continued research into the pathogenesis of this complex and multifactorial disease will help provide more understanding into disease targets and how to best approach treatment.

Bibliography

1. Alikhan A., *et al*. "Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up". *Journal of the American Academy of Dermatology* 65.3 (2011): 473-491.

2. Yamamoto Y., *et al*. "Application of a two-question screening instrument to detect depressive symptoms in patients with vitiligo: a pilot study". *Journal of the American Academy of Dermatology* 64.5 (2011): e69-e70.

3. Taïeb A., *et al*. "The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force". *Pigment Cell Research* 20.1 (2007): 27-35.

4. Linthorst Homan MW., *et al*. "The burden of vitiligo: patient characteristics associated with quality of life". *Journal of the American Academy of Dermatology* 61.3 (2009): 411-420.

5. Boissy RE and Manga P. "On the etiology of contact/occupational vitiligo". *Pigment Cell Research* 17.3 (2004): 208-214.

6. Ezzedine K., *et al*. "Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference". *Pigment Cell and Melanoma Research* 25.3 (2012): E1-E13.

7. van Geel N, *et al*. "Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative". *Journal of Investigative Dermatology* 136.5 (2016): 978-984.

8. Eleftheriadou V., *et al*. "Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus". *Pigment Cell and Melanoma Research* 28.3 (2015): 363-369.

9. Spritz RA. "The genetics of generalized vitiligo". *Current Directions in Autoimmunity* 10 (2008): 244-257.

10. Jin Y., *et al*. "Genome-Wide Analysis Identifies a Quantitative Trait Locus in the MHC Class II Region Associated with Generalized Vitiligo Age of Onset". *Journal of Investigative Dermatology* 131.6 (2011): 1308-1312.

11. Halder R and Taliaferro S. "Vitiligo". Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, eds. Fitzpatrick's Dermatology in General Medicine. 7th edition. New York, NY: McGraw-Hill 1 (2008): 72.

12. van Geel N., *et al*. "Koebner's phenomenon in vitiligo: European position paper". *Pigment Cell and Melanoma Research* 24.3 (2011): 564-573.

13. Lee DY., *et al*. "The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment". *International Journal of Dermatology* 50.8 (2011): 925-927.

14. Hann S-K. "Clinical variants of vitiligo". Lotti T, Hercogova J, eds. Vitiligo: Problems and Solutions. New York, NY: Marcel Dekker (2004): 159-173.

15. Ezzedine K., *et al*. "Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients". *British Journal of Dermatology* 165.1 (2011): 44-49.

16. Ohguchi R., *et al*. "Risk factors and treatment responses in patients with vitiligo in Japan-A retrospective large-scale study". *Kaohsiung Journal of Medical Sciences* 31.5 (2015): 260-264.

17. Schallreuter KU., *et al*. "Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?" *Experimental Dermatology* 17.2 (2008): 139-160.

18. Do JE., *et al*. "The effect of 308 nm excimer laser on segmental vitiligo: a retrospective study of 80 patients with segmental vitiligo". *Photodermatology, Photoimmunology and Photomedicine* 27.3 (2011): 147-151.

19. Saraceno R., *et al*. "Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study". *Dermatology and Therapy* 22.4 (2009): 391-394.

20. Matz H and Tur E. "Vitiligo". *Current Problems in Dermatology* 35 (2007): 78-102.

21. Bae JM., *et al*. "Phototherapy for Vitiligo: A Systematic Review and Meta-analysis". *JAMA Dermatology* 153.7 (2017): 666-674.

22. Grimes PE., *et al*. "The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo". *JAMA Dermatology* 149.1 (2013): 68-73.

23. Lim HW., *et al*. "Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial". *JAMA Dermatology* 151.1 (2015): 42-50.

24. Graham A., *et al*. "The expression of alpha-MSH by melanocytes is reduced in vitiligo". *Annals of the New York Academy of Sciences* 885 (1999): 470-473.

25. Dillon AB., *et al*. "Advances in Vitiligo: An Update on Medical and Surgical Treatments". *Journal of Clinical and Aesthetic Dermatology* 10.1 (2017): 15-28.

26. Garg BJ., *et al*. "Topical treatment in vitiligo and the potential uses of new drug delivery systems". *Indian Journal of Dermatology, Venereology and Leprology* 76.3 (2010): 231-238.

27. Rothstein B., *et al*. "Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib". *Journal of the American Academy of Dermatology* 76.6 (2017): 1054-1060.

28. Grau C and Silverberg NB. "Vitiligo patients seeking depigmentation therapy: a case report and guidelines for psychological screening". *Cutis* 91.5 (2013): 248-252.

29. Chimento SM., *et al*. "A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo". *Journal of Drugs in Dermatology* 7.3 (2008): 258-263.

30. AlGhamdi KM and Kumar A. "Depigmentation therapies for normal skin in vitiligo universalis". *Journal of the European Academy of Dermatology and Venereology* 25.7 (2011): 749-757.

31. Birlea SA., *et al*. "Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation". *Current Drug Targets* 9.4 (2008): 345-359.

32. Akdeniz N., *et al*. "Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo". *Journal of Dermatological Treatment* 25.3 (2014): 196-199.

33. Khullar G., *et al*. "Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial". *Journal of the European Academy of Dermatology and Venereology* 29.5 (2015): 925-932.

34. Ermis O., *et al*. "Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study". *British Journal of Dermatology* 145.3 (2001): 472-475.

35. Esfandiarpour I., *et al*. "The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial". *Journal of Dermatological Treatment* 20.1 (2009): 14-18.

36. Gou D., *et al*. "Suction blister grafting for vitiligo: efficacy and clinical predictive factors". *Dermatologic Surgery* 41.5 (2015): 633-639.

37. Ghosh D., *et al*. "Efficacy and safety of autologous cultured melanocytes delivered on poly (DL-lactic acid) film: a prospective, open-label, randomized, multicenter study". *Dermatologic Surgery* 38.12 (2012): 1981-1990.

38. Huggins RH., *et al*. "Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States". *Journal of the American Academy of Dermatology* 66.5 (2012): 785-793.

Volume SI Issue 1 August 2017